We conducted a retrospective analysis to investigate the influence of LMR on clinical outcomes including progression-free survival (PFS) and overall survival (OS) in EGFR-mutant patients with NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.